The Value of Genetics in Stroke Management — by BValue

The Value of Genetics in Stroke Management — by BValue

BValue Successfully Launched the Official Genetic Test – Genedrive® CYP2C19 During the World Stroke Congress

BValue is proud to announce the official launch of Genedrive® CYP2C19, the first and only point-of-care (POC) genetic test for stroke patients in Spain. The launch took place from October 22nd to 24th during the prestigious World Stroke Congress.

The Genedrive CYP2C19 test leverages rapid PCR technology to deliver 99.9% reliable results in under 69 minutes — directly at the point of care. It enables immediate identification of patients who are non-metabolisers of Clopidogrel, a genetic variant found in up to 30% of the European population. These patients face a significantly higher risk of recurrent cerebrovascular events if standard therapy is used.

With this solution, clinicians can now personalise antiplatelet therapy within the first 24 hours after a stroke or TIA, in line with the NICE Guidelines (UK), which recommend Genedrive CYP2C19 testing when laboratory results are not available in time.

Clopidogrel remains the most prescribed antiplatelet therapy, yet genetic resistance can render it ineffective in a large subset of patients. Dual antiplatelet therapy (DAPT) — typically combining aspirin with Clopidogrel or Ticagrelor — is recommended by both U.S. and EU Guidelines to be initiated within 12–24 hours following a minor stroke or high-risk TIA. However, conventional lab testing often fails to provide actionable results within this critical window.

By introducing a validated, bedside genotyping tool, BValue empowers stroke teams to make faster, more precise treatment decisions — helping to reduce the risk of recurrent events by up to 30%, as supported by evaluations from NICE in the UK.

With this launch, BValue reinforces its commitment to value-based healthcare, enabling better clinical outcomes, more efficient use of public resources, and wider access to precision medicine in the management of Stroke and TIA.